Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma

Clinical Cancer Research

Volumn 16, Issue 16, 2010, Pages 4077-4083

  Erkizan, Hayriye V ^a   Uversky, Vladimir N ^b,c   Toretsky, Jeffrey A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; AURORA KINASE INHIBITOR; COMPLEMENTARY RNA; HYBRID PROTEIN; MLN 8237; NANOPARTICLE; ONCOPROTEIN; RECOMBINANT PROTEIN; RNA BINDING PROTEIN EWS; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTOME; UNCLASSIFIED DRUG; YK 279;

CARCINOGENESIS; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; DNA SPLICING; EWING SARCOMA; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SPLICEOSOME; TRANSCRIPTION REGULATION; VIRION; VIRUS CARCINOGENESIS;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENE PROTEINS, FUSION; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 77955729370     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2261     Document Type: Review

References (73)

1. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the- art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20:412-8.
2. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-9.
3. Riggi N, Suva ML, Stamenkovic I. Ewing's sarcoma origin: from duel to duality. Expert Rev Anticancer Ther 2009;9:1025-30.
4. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005;15:189-96.
5. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
6. May WA, Lessnick SL, Braun BS, et al. The Ewing's sarcoma EWS/ FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 1993;13:7393-8.
7. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994; 14:3230-41.
8. Aryee DN, Sommergruber W, Muehlbacher K, Dockhorn-Dworniczak B, Zoubek A, Kovar H. Variability in gene expression patterns of Ewing tumor cell lines differing in EWS-FLI1 fusion type. Lab Invest 2000; 80:1833-44.
9. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-9.
10. Uren A, Toretsky JA. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 2005;1:521-8.
11. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000;275:24865-71.
12. Uren A, Tcherkasskaya O, Toretsky JA. Recombinant EWS-FLI1 on-coprotein activates transcription. Biochemistry 2004;43:13579-89.
13. Ng KP, Potikyan G, Savene RO, Denny CT, Uversky VN, Lee KA. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proc Natl Acad Sci U S A 2007;104:479-84.
14. Siligan C, Ban J, Bachmaier R, et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 2005;24:2512-24.
15. Nielsen TO. Microarray analysis of sarcomas. Adv Anat Pathol 2006; 13:166-73.
16. Liu L, Westler WM, den Boon JA, et al. An amphipathic α-helix controls multiple roles of brome mosaic virus protein 1a in RNA replication complex assembly and function. PLoS Pathog 2009;5:e1000351.
17. Dunker AK, Obradovic Z, Romero P, Garner EC, Brown CJ. Intrinsic protein disorder in complete genomes. Genome Inform Ser Workshop Genome Inform 2000;11:161-71.
18. Ward JJ, Sodhi JS, McGuffin LJ, Buxton BF, Jones DT. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol 2004;337:635-45.
19. Mittag T, Orlicky S, Choy WY, et al. Dynamic equilibrium engagement of a polyvalent ligand with a single-site receptor. Proc Natl Acad Sci U S A 2008;105:17772-7.
20. Uversky VN, Oldfield CJ, Dunker AK. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys 2008;37:215-46.
21. Zhang WD, Xie CM, Mo YX, Li JY. [CT and MRI features of peripheral primitive neuroectodermal tumor] [Article in Chinese]. Ai Zheng 2007; 26:643-6.
22. Watson DK, Robinson L, Hodge DR, Kola I, Papas TS, Seth A. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Oncogene 1997;14:213-21.
23. Kim S, Denny CT, Wisdom R. Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins. Mol Cell Biol 2006;26:2467-78.
24. Arvand A, Welford SM, Teitell MA, Denny CT. The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1. Cancer Res 2001;61:5311-7.
25. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol 1998;18:1489-97.
26. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998;17:603-10.
27. Yang L, Chansky HA, Hickstein DD. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 2000;275:37612-8.
28. Ramakrishnan R, Fujimura Y, Zou JP, et al. Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1. Oncogene 2004;23:7087-94.
29. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/ CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003;278:15105-15.
30. Spahn L, Petermann R, Siligan C, Schmid JA, Aryee DN, Kovar H. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Res 2002;62:4583-7.
31. Toretsky JA, Erkizan V, Levenson A, et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res 2006;66: 5574-81.
32. Nakajima T, Uchida C, Anderson SF, et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 1997;90:1107-12.
33. Hartman TR, Qian S, Bolinger C, Fernandez S, Schoenberg DR, Boris-Lawrie K. RNA helicase A is necessary for translation of selected messenger RNAs. Nat Struct Mol Biol 2006;13:509-16.
34. Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009;15:750-6.
35. Mendiola M, Carrillo J, Garcia E, et al. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 2006;118:1381-9.
36. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res 2006;4:851-9.
37. Garcia-Aragoncillo E, Carrillo J, Lalli E, et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. Oncogene 2008;27:6034-43.
38. Kinsey M, Smith R, Iyer AK, McCabe ER, Lessnick SL. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res 2009;69: 9047-55.
39. Knoop LLBS. EWS/FLI alters 5′-splice site selection. J Biol Chem 2001;276:22317-22.
40. Chansky HA, Hu M, Hickstein DD, Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 2001;61:3586-90.
41. Sanchez G, Bittencourt D, Laud K, et al. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci U S A 2008;105:6004-9.
42. Pahlich S, Quero L, Roschitzki B, Leemann-Zakaryan RP, Gehring H. Analysis of Ewing sarcoma (EWS)-binding proteins: interaction with hnRNP M, U, and RNA-helicases p68/72 within protein-RNA complexes. J Proteome Res 2009;8:4455-65.
43. Klevernic IV, Morton S, Davis RJ, Cohen P. Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J 2009;418:625-34.
44. Bachmaier R, Aryee DN, Jug G, et al. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Oncogene 2009;28:1280-4.
45. Kauer M, Ban J, Kofler R, et al. A molecular function map of Ewing's sarcoma. PLoS ONE 2009;4:e5415-7.
46. Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 2008;68:2176-85.
47. Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A 2009;106:5324-9.
48. Tirado OM, Mateo-Lozano S, Villar J, et al. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 2006; 66:9937-47.
49. Wakahara K, Ohno T, Kimura M, et al. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res 2008;6:1937-45.
50. Takahashi A, Higashino F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003;63:8338-44.
51. Deneen B, Hamidi H, Denny CT. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res 2003;63:4268-74.
52. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 2009;28:4126-32.
53. Nozawa S, Ohno T, Banno Y, et al. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells. J Biol Chem 2005;280:27544-51.
54. Zwerner JP, Joo J, Warner KL, et al. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2008;27:3282-91.
55. Beauchamp E, Bulut G, Abaan O, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009;284:9074-82.
56. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-7.
57. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47.
58. Toretsky JA, Connell Y, Neckers L, Bhat NK. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997;31:9-16.
59. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049-54.
60. Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7:429-37.
61. Maksimenko A, Lambert G, Bertrand JR, Fattal E, Couvreur P, Malvy C. Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Ann N Y Acad Sci 2003;1002:72-7.
62. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92.
63. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to over-saturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41.
64. Grohar PJ, Woldemichael G, Griffin L, et al. Identification of transcription factor inhibitors: a method used to identify small molecules that block EWS-FLI1 transcription activity. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO. 2009, Philadelphia (PA): AACR; 2009. Abstract nr 3805.
65. Li R, Pei H, Watson DK. Regulation of Ets function by protein-protein interactions. Oncogene 2000;19:6514-23.
66. Sillerud LO, Larson RS. Design and structure of peptide and pepti-domimetic antagonists of protein-protein interaction. Curr Protein Pept Sci 2005;6:151-69.
67. Pagliaro L, Felding J, Audouze K, et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004;8:442-9.
68. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 2004;3:301-17.
69. Murray JK, Gellman SH. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers 2007;88:657-86.
70. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34.
71. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010;54:921-6.
72. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13:1322-30.
73. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35.